Hemodialysis is the most used treatment option in the world and in our country. Sick individuals also encounter many complications after starting treatment. One of them, renalosteodystrophy, is tissue damage that occurs in the bones.
When patients with end-stage renal disease start dialysis, there are no bone-related symptoms yet. However, laboratory findings of asymptomatic bone disease can be seen. With the third stage, that is, after the glomerular filtration value (GFR) begins to fall below 60 ml/min/1.73m2, mineral and bone disease occurs and laboratory findings begin to deteriorate.
Patients develop symptoms such as hypocalcemia, decreased vitamin D production, and hyperphosphatemia, and as a result, renalosteodystrophy develops.
In CRF, after stage 3, decreases in calcium level and active vitamin D production, and increases in parathormone and phosphate values occur. This results in mineral metabolism disorders such as vitamin D deficiency, hyperparathyroidism, hypocalcemia and hyperphosphatemia, and bone tissue disorders occur in patients.
LECTURER EMİNE HAS
